Table 2 Pathway analysis
Pathway name | Gene set size | Genes contained | p-value | q-value | Source |
|---|---|---|---|---|---|
Granulomatous tissue | |||||
Cytokine-cytokine receptor interaction | 294 | 37 (12.6%) | 1.5E−20 | 4.2E−19 | KEGG |
Chemokine signalling pathway | 189 | 24 (12.7%) | 9.8E−14 | 1.4E−12 | KEGG |
VEGFA-VEGFR2 Signaling Pathway | 236 | 26 (11.0%) | 2.6E−13 | 2.4E−12 | Wikipathways |
PI3K-Akt signalling pathway | 354 | 31 (8.8%) | 5.6E−13 | 3.9 E−12 | KEGG |
Focal Adhesion-PI3K-Akt-mTOR-signaling | 302 | 28 (9.3%) | 2.2E−12 | 1.2E−11 | Wikipathways |
PI3K-Akt Signaling Pathway | 340 | 29 (8.6%) | 6.4E−12 | 3E−11 | Wikipathways |
Pathways in cancer | 526 | 36 (6.8%) | 1.1E−11 | 4.4E−11 | KEGG |
Focal Adhesion | 198 | 22 (11.1%) | 1.7E−11 | 5.8E−11 | Wikipathways |
Extracellular matrix organization | 294 | 26 (8.8%) | 4.1E−11 | 1.3E−10 | Reactome |
Focal adhesion | 199 | 21 (10.6%) | 1.3E−10 | 3.6E−10 | KEGG |
Human papillomavirus infection | 339 | 23 (6.8%) | 8.9E−08 | 2.3E−07 | KEGG |
Signal Transduction | 2647 | 82 (3.1%) | 4.1E−07 | 9.1E−07 | Reactome |
Cytokine Signaling in Immune system | 458 | 26 (5.7%) | 4.2E−07 | 9.1E−07 | Reactome |
Immune System | 1840 | 63 (3.4%) | 5.2E−07 | 1E−06 | Reactome |
MAPK signalling pathway | 295 | 20 (6.8%) | 6.5E−07 | 1.2E−06 | KEGG |
JAK STAT pathway and regulation | 310 | 20 (6.5%) | 1.3E−06 | 2.3E−06 | INOH |
Signaling by Receptor Tyrosine Kinases | 423 | 21 (5.0%) | 4.3E−05 | 7.1E−05 | Reactome |
GPCR ligand binding | 466 | 22 (4.7%) | 5.8E−05 | 9.1E−05 | Reactome |
Hemostasis | 668 | 25 (3.7%) | 0.00069 | 0.00101 | Reactome |
Adaptive Immune System | 732 | 25 (3.4%) | 0.00232 | 0.00324 | Reactome |
Innate Immune System | 1077 | 31 (2.9%) | 0.00852 | 0.0114 | Reactome |
Sarcoidosis exclusively | |||||
VEGFA-VEGFR2 Signaling Pathway | 236 | 12 (5.1%) | 1.97E−08 | 2.76E−07 | Wikipathways |
MAPK signalling pathway | 295 | 11 (3.7%) | 1.79E−06 | 1.25E−05 | KEGG |
Diseases of signal transduction | 248 | 10 (4.0%) | 2.73E−06 | 1.27E−05 | Reactome |
Focal Adhesion-PI3K-Akt-mTOR-signaling | 302 | 10 (3.3%) | 1.55E−05 | 5.42E−05 | Wikipathways |
Nuclear Receptors Meta-Pathway | 316 | 10 (3.2%) | 2.29E−05 | 6.41E−05 | Wikipathways |
Signaling by Receptor Tyrosine Kinases | 423 | 11 (2.6%) | 5.30E−05 | 0.00012 | Reactome |
PI3K-Akt signalling pathway | 354 | 10 (2.8%) | 5.86E−05 | 0.00012 | KEGG |
Pathways in cancer | 526 | 11 (2.1%) | 0.00036 | 0.00063 | KEGG |
Signal Transduction | 2647 | 29 (1.1%) | 0.00065 | 0.00102 | Reactome |
Disease | 510 | 10 (2.0%) | 0.00108 | 0.00151 | Reactome |
JAK STAT pathway and regulation | 310 | 9 (2.9%) | 0.00011 | 0.00025 | INOH |
PI3K-Akt Signaling Pathway | 340 | 9 (2.7%) | 0.00023 | 0.00046 | Wikipath |
EGFR1 | 457 | 9(2.0%) | 0.00187 | 0.00257 | NEtPath |